SOUTH SAN FRANCISCO, California, Nov. 11 -- Genentech, a member of the Roche Group, issued the following news release:

* * *

Genentech and Roche Present New Data Across Pharmaceuticals and Diagnostics From Its Growing Alzheimer's Disease Portfolio at CTAD 2026

* Updated Phase Ib/IIa Brainshuttle(TM) AD study data for trontinemab demonstrating rapid amyloid removal dynamics and changes in key biomarkers

* Phase III PrevenTRON study design . . .

Click here for more information about our products